In-vitro activity of teicoplanin alone and in combination with rifampicin, gentamicin or tobramycin against coagulase-negative staphylococci.
The in vitro activity of teicoplanin and the effect of the combination of teicoplanin and rifampicin, gentamicin or tobramycin against 50 strains of coagulase-negative staphylococci isolated from blood cultures were studied. All strains of coagulase-negative staphylococci were inhibited by teicoplanin less than or equal to 8 mg/l. The combination of teicoplanin and rifampicin was synergistic against 29 strains and antagonistic against one strain. The combination of teicoplanin and gentamicin or tobramycin showed synergism or antagonism against only a few strains.
D003030:Coagulase / Q000378:metabolism; D004357:Drug Synergism; D005839:Gentamicins / Q000494:pharmacology*; D006020:Glycopeptides / Q000494:pharmacology; D008826:Microbial Sensitivity Tests; D012293:Rifampin / Q000494:pharmacology*; D013210:Staphylococcus / Q000187:drug effects* / Q000378:metabolism; D017334:Teicoplanin; D014031:Tobramycin / Q000494:pharmacology*
D003030:Coagulase; D005839:Gentamicins; D006020:Glycopeptides; D017334:Teicoplanin; D012293:Rifampin; D014031:Tobramycin